Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
Prof. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany
Similar Posts
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeysInnokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
Patent Granted for “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in Russia
ByInnokeysNew patent is granted with the title of “Treatment of Patients Diagnosed with Pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR”…
Webinar – Nimotuzumab for Head and Neck Cancer Indication: A randomized phase 3 trial of Nimotuzumab in locally advanced head and neck cancer
ByInnokeysSpeaker: Prof. Dr. Kumar Prabhash, Medical Oncologist in Tata Memorial Hospital India The webinar was attended by more than 50…
Webinar – Clinical Experience of Using Nimotuzumab in Nasopharyngeal Cancer
ByInnokeysSpeaker: Dr. dr. Andhika Rachman, Sp.Pd-KHOM from MRCCC Siloam Hospital Indonesia
New Marketing Authorization Approval in Myanmar for locally advanced unresectable or metastatic pancreatic cancer
ByInnokeysNew marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer is approved in Myanmar by the Myanmar FDA. This indication…
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeysKowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….